A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Fluzoparib Monotherapy in Patients With gBRCA/PALB2 Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Latest Information Update: 01 Apr 2024
At a glance
- Drugs Fuzuloparib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 27 Mar 2024 Status changed from recruiting to discontinued due to adjustment in Research and Development strategy by the sponsor.
- 18 Aug 2020 Status changed from not yet recruiting to recruiting.
- 13 Jul 2020 Planned initiation date changed from 1 Jul 2020 to 1 Aug 2020.